Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Oct 16;31(12):632.
doi: 10.1007/s00520-023-08099-2.

Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study

Yusuke Hiratsuka  1   2 , Keita Tagami  3 , Akira Inoue  3 , Mamiko Sato  3 , Yasufumi Matsuda  3 , Kazuhiro Kosugi  4 , Emi Kubo  4 , Maika Natsume  4 , Hiroto Ishiki  5 , Sayaka Arakawa  5 , Masaki Shimizu  6 , Naosuke Yokomichi  7 , Shih-Wei Chiu  8 , Mayu Shimoda  8 , Hideyuki Hirayama  9 , Kaoru Nishijima  10 , Kota Ouchi  11 , Tatsunori Shimoi  12 , Tomoko Shigeno  9 , Takuhiro Yamaguchi  8 , Mitsunori Miyashita  9 , Tatsuya Morita  7   13 , Eriko Satomi  5
Affiliations
Multicenter Study

Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study

Yusuke Hiratsuka et al. Support Care Cancer. .

Abstract

Purpose: Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common. To date, little is known about the differences in risks of AEs by opioid type. This study was performed to compare the prevalence of AEs across opioids commonly used for analgesic treatment in Japan.

Methods: This study was conducted as a preplanned secondary analysis of a multicenter prospective longitudinal study of inpatients with cancer pain who received specialized palliative care for cancer pain relief. We assessed daily AEs until termination of follow-up. We rated the severity of AEs based on the Common Terminology Criteria for Adverse Events version 5.0. We computed adjusted odds ratios for each AE (constipation, nausea and vomiting, delirium, and drowsiness) with the following variables: opioid, age, sex, renal dysfunction, and primary cancer site.

Results: In total, 465 patients were analyzed. Based on the descriptive analysis, the top four most commonly used opioids were included in the analysis: oxycodone, hydromorphone, fentanyl, and tramadol. With respect to the prevalence of AEs among all analyzed patients, delirium (n = 25, 6.3%) was the most frequent, followed by drowsiness (n = 21, 5.3%), nausea and vomiting (n = 19, 4.8%), and constipation (n = 28, 4.6%). The multivariate logistic analysis showed that no single opioid was identified as a statistically significant independent predictor of any AE.

Conclusion: There was no significant difference in the prevalence of AEs among oxycodone, fentanyl, hydromorphone, and tramadol, which are commonly used for analgesic treatment in Japan.

Keywords: Advanced cancer; Adverse event; Opioid; Specialized palliative care.

PubMed Disclaimer

Conflict of interest statement

The authors have reported the COI via ICMJE disclosure form. The corresponding author has submitted the forms as supplementary files.

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Similar articles

See all similar articles

Cited by

References

    1. Kroenke K, Theobald D, Wu J, Loza JK, Carpenter JS, Tu W. The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients. J Pain Symptom Manage. 2010;40:327–341. doi: 10.1016/j.jpainsymman.2009.12.023. - DOI - PMC - PubMed
    1. Snijders RAH, Brom L, Theunissen M, et al. Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel) 2023;15:591. doi: 10.3390/cancers15030591. - DOI - PMC - PubMed
    1. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–e68. doi: 10.1016/S1470-2045(12)70040-2. - DOI - PubMed
    1. Swarm RA, Dans M. NCCN frameworks for resource stratification of NCCN guidelines: adult cancer pain and palliative care. J Natl Compr Canc Netw. 2018;16:628–631. doi: 10.6004/jnccn.2018.0044. - DOI - PubMed
    1. Corli O, Santucci C, Corsi N, et al. The burden of opioid adverse events and the influence on cancer patients’ symptomatology. J Pain Symptom Manage. 2019;57:899–908.e6. doi: 10.1016/j.jpainsymman.2019.02.009. - DOI - PubMed

Publication types